Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy
Background: Checkpoint inhibitors show impressive and durable responses in various cancer types and provide new avenues for cancer immunotherapy. However, these drugs have a variety of adverse events. Common autoimmune-related adverse effects include fatigue, hepatitis, skin rash, endocrine deficien...
Main Authors: | Saskia Bolz, Thivyah Ramakrishnan, Michael Fleischer, Elisabeth Livingstone, Benjamin Stolte, Andreas Thimm, Kathrin Kizina, Selma Ugurel, Christoph Kleinschnitz, Martin Glas, Lisa Zimmer, Tim Hagenacker |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-03-01
|
Series: | eNeurologicalSci |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405650221000162 |
Similar Items
-
Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literature
by: Lisa M. Cordes, et al.
Published: (2020-01-01) -
Evidence from a meta-analysis: is nivolumab neurotoxic in cancer patients?
by: Kong X, et al.
Published: (2017-03-01) -
Cancer immunotherapy experience in the Integral Oncology Centre “Diana Laura Riojas de Colosio”, Médica Sur Hospital
by: Ricardo Fernández-Ferreira, et al.
Published: (2019-12-01) -
Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management
by: Takahiro Yanase, et al.
Published: (2021-01-01) -
Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod
by: Taku Fujimura, et al.
Published: (2018-01-01)